186 filings
6-K
CVAC
CureVac N.V.
16 Apr 24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4:15pm
144
Greune Malte
12 Apr 24
Notice of proposed sale of securities
4:48pm
6-K
CVAC
CureVac N.V.
4 Apr 24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4:15pm
SC 13G/A
Ra Capital Management, LLC
14 Feb 24
CureVac / RA CAPITAL MANAGEMENT ownership change
5:01pm
SC 13G/A
CVAC
CureVac N.V.
6 Feb 24
CureVac / GSK ownership change
5:10pm
6-K
rpa2ko5
17 Jan 24
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
9:02am
6-K
pem2dfrvsa w2cp18t
5 Jan 24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
4:15pm
144
6u4nng t2l9mqc6r1
5 Jan 24
Notice of proposed sale of securities
3:19pm
144
0z6su5l55wev3
5 Jan 24
Notice of proposed sale of securities
3:09pm
144
gk15 0u7j4
5 Jan 24
Notice of proposed sale of securities
2:57pm
144
it0cfppvpwt5yniy
5 Jan 24
Notice of proposed sale of securities
2:41pm
6-K
48f540y6slqlkk
19 Dec 23
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
4:30pm
6-K
nt9 qs08a
14 Nov 23
Current report (foreign)
4:15pm
6-K
oizspchf6w0tdj0sh0q
14 Nov 23
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
4:15pm
6-K
kuuillt6
1 Nov 23
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
4:45pm
UPLOAD
qpiey
19 Oct 23
Letter from SEC
12:00am
20-F/A
4nca15y9vl
12 Oct 23
Annual report (foreign) (amended)
4:15pm
CORRESP
w2ywejl274arobxqr
10 Oct 23
Correspondence with SEC
12:00am
6-K
76fjtkws597k nw6iuq1
28 Sep 23
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
4:30pm
UPLOAD
sp1yx
26 Sep 23
Letter from SEC
12:00am